icad inc (ICAD) - Cash Flow Conversion Efficiency

Latest as of March 2025: 0.002x

Based on the latest financial reports, icad inc (ICAD) has a cash flow conversion efficiency ratio of 0.002x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($60.00K) by net assets ($30.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

icad inc - Cash Flow Conversion Efficiency Trend (1988–2024)

This chart illustrates how icad inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does icad inc carry for a breakdown of total debt and financial obligations.

icad inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of icad inc ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Dmc Global Inc
NASDAQ:BOOM
0.035x
Avadh Sugar & Energy Limited
NSE:AVADHSUGAR
0.864x
TCM Group
CO:TCM
0.009x
Kimlun Corporation Bhd
KLSE:5171
-0.030x
Yi Jinn Industrial Co Ltd
TW:1457
0.004x
Energy World Corporation Ltd
AU:EWC
-0.017x
GSD Holding AS
IS:GSDHO
0.028x
Michael Hill International Ltd
AU:MHJ
-0.015x

Annual Cash Flow Conversion Efficiency for icad inc (1988–2024)

The table below shows the annual cash flow conversion efficiency of icad inc from 1988 to 2024. For the full company profile with market capitalisation and key ratios, see icad inc market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 $28.68 Million $-3.94 Million -0.138x +7.41%
2023-12-31 $33.42 Million $-4.96 Million -0.149x +59.46%
2022-12-31 $34.90 Million $-12.79 Million -0.366x -81.18%
2021-12-31 $46.52 Million $-9.41 Million -0.202x +11.62%
2020-12-31 $30.52 Million $-6.99 Million -0.229x +83.67%
2019-12-31 $5.07 Million $-7.11 Million -1.401x -149.93%
2018-12-31 $6.90 Million $-3.87 Million -0.561x -9.11%
2017-12-31 $14.28 Million $-7.34 Million -0.514x -134.90%
2016-12-31 $25.04 Million $-5.48 Million -0.219x -277.07%
2015-12-31 $32.75 Million $-1.90 Million -0.058x -213.69%
2014-12-31 $62.78 Million $3.20 Million 0.051x +176.62%
2013-12-31 $21.38 Million $-1.42 Million -0.067x +56.16%
2012-12-31 $27.66 Million $-4.20 Million -0.152x +45.98%
2011-12-31 $36.05 Million $-10.14 Million -0.281x -10032.78%
2010-12-31 $73.21 Million $207.33K 0.003x -94.55%
2009-12-31 $66.31 Million $3.44 Million 0.052x -64.80%
2008-12-31 $66.29 Million $9.78 Million 0.147x +1153.97%
2007-12-31 $48.85 Million $574.57K 0.012x +112.79%
2006-12-31 $47.97 Million $-4.41 Million -0.092x -273.93%
2005-12-31 $52.73 Million $-1.30 Million -0.025x +28.16%
2004-12-31 $56.97 Million $-1.95 Million -0.034x +64.87%
2003-12-31 $47.90 Million $-4.67 Million -0.097x +7.33%
2002-12-31 $21.46 Million $-2.26 Million -0.105x +84.43%
2001-12-31 $2.04 Million $-1.38 Million -0.675x -241.10%
2000-12-31 $2.90 Million $-574.33K -0.198x +40.63%
1999-12-31 $3.00 Million $-1.00 Million -0.333x +63.49%
1998-12-31 $2.30 Million $-2.10 Million -0.913x -172.19%
1997-12-31 $3.40 Million $4.30 Million 1.265x +618.53%
1996-12-31 $4.10 Million $-1.00 Million -0.244x -72.76%
1995-12-31 $8.50 Million $-1.20 Million -0.141x -374.29%
1994-12-31 $13.60 Million $700.00K 0.051x -85.38%
1993-12-31 $12.50 Million $4.40 Million 0.352x +396.71%
1992-12-31 $12.70 Million $900.00K 0.071x +216.22%
1991-12-31 $8.20 Million $-500.00K -0.061x +83.36%
1990-12-31 $13.10 Million $-4.80 Million -0.366x -131.81%
1988-12-31 $7.90 Million $9.10 Million 1.152x --

About icad inc

NASDAQ:ICAD USA Medical Devices
Market Cap
$106.31 Million
Market Cap Rank
#18943 Global
#4178 in USA
Share Price
$3.87
Change (1 day)
+3.75%
52-Week Range
$3.48 - $3.99
All Time High
$21.22
About

iCAD, Inc. provides AI-powered cancer detection solutions in the United States. The company's ProFound Breast Health Suite offers solutions for"breast"cancer detection, breast density assessment, one- or two-year breast cancer risk evaluation, and cardiovascular risk assessment related to elevated levels of breast arterial calcifications; and enables medical providers and professionals to accurat… Read more